Regeneron Pharmaceuticals Inc
NASDAQ:REGN

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Watchlist
Price: 750.52 USD 0.81% Market Closed
Market Cap: 82.5B USD
Have any thoughts about
Regeneron Pharmaceuticals Inc?
Write Note

Regeneron Pharmaceuticals Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Regeneron Pharmaceuticals Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Interest Income Expense
$990m
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Interest Income Expense
-$2B
CAGR 3-Years
7%
CAGR 5-Years
-9%
CAGR 10-Years
-13%
Gilead Sciences Inc
NASDAQ:GILD
Interest Income Expense
-$948m
CAGR 3-Years
26%
CAGR 5-Years
-6%
CAGR 10-Years
-10%
Amgen Inc
NASDAQ:AMGN
Interest Income Expense
-$2.4B
CAGR 3-Years
-34%
CAGR 5-Years
-29%
CAGR 10-Years
-15%
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Interest Income Expense
-$138.5m
CAGR 3-Years
-15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Interest Income Expense
$598m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Regeneron Pharmaceuticals Inc
Glance View

Market Cap
82.6B USD
Industry
Biotechnology

Regeneron Pharmaceuticals Inc., based in Tarrytown, New York, has established itself as a powerhouse in the biopharmaceutical industry, primarily focusing on the development of innovative treatments for serious medical conditions. Founded in 1988, the company has built a robust pipeline of cutting-edge drugs that address a variety of diseases, including eye disorders, cancer, and autoimmune diseases. Regeneron's flagship product, Eylea, has transformed the treatment of retinal diseases, generating significant revenue and proving the company's capability to bring breakthrough therapies to market. The company's strong commitment to research and development is complemented by its proprietary VelociGene and VelociMouse technologies, which facilitate rapid and effective drug discovery. Investors are drawn to Regeneron not only for its impressive product portfolio but also for its strong financial performance and strategic collaborations. The company's unique approach combines scientific rigor with entrepreneurial spirit, allowing it to navigate the complex landscape of pharmaceutical development successfully. Regeneron's partnership with international health organizations during the COVID-19 pandemic, particularly through its antibody treatments, showcased its agility and dedication to public health. With a solid balance sheet and an unwavering focus on innovation, Regeneron Pharmaceuticals stands out as a compelling investment opportunity in the biotechnology sector, poised for continued growth and success in addressing critical healthcare needs.

REGN Intrinsic Value
534.16 USD
Overvaluation 29%
Intrinsic Value
Price

See Also

What is Regeneron Pharmaceuticals Inc's Interest Income Expense?
Interest Income Expense
990m USD

Based on the financial report for Sep 30, 2024, Regeneron Pharmaceuticals Inc's Interest Income Expense amounts to 990m USD.

What is Regeneron Pharmaceuticals Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
23%

Over the last year, the Interest Income Expense growth was 609%. The average annual Interest Income Expense growth rates for Regeneron Pharmaceuticals Inc have been 23% over the past three years .

Back to Top